Inthera Bioscience
Develops small molecular therapies for solid tumours.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | €4.7m | Series A | |
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Inthera Bioscience is an emerging Swiss biotechnology company focused on developing innovative and highly effective therapies for currently incurable cancers. The company specializes in designing small molecule inhibitors that target intracellular protein-protein interactions, a novel approach in cancer treatment. Their most advanced therapeutic candidate, a modulator of dysregulated transcription, is progressing towards clinical trials. Inthera Bioscience serves the oncology market, primarily targeting patients with cancers that have limited or no treatment options. The company operates on a research and development business model, generating revenue through partnerships, grants, and potential future sales of their therapeutic products.
Keywords: biotechnology, cancer therapy, small molecule inhibitors, protein interactions, oncology, clinical trials, innovative chemistry, Swiss company, drug development, incurable cancers.